We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ranbaxy may join the bidding war for Merck KGaA’s generic drugs division, according to a company source who confirmed reports of the generic firm’s interest in acquiring the billion-dollar division.
A federal antitrust lawsuit filed by drug distributors against Purdue Pharma claims the drug company monopolized the OxyContin market by blocking generic versions of the drug with illegally obtained patents.
The authors of the legislation that paved the way for improved market access for generic drug firms are confident that legislation to facilitate biogeneric entry is likely to move forward before the end of 2007.
Separate earnings reports released by Barr and Watson show expenses and other charges related to acquisition activity were key factors that drove earnings downward for both companies in 2006.
The authors of the legislation that paved the way for improved market access for generic drug firms are confident that legislation to facilitate biogeneric entry is likely to move forward before the end of 2007.
One of the federal investigations into a reverse-payment deal involving generic Plavix found no violations of federal securities laws on the part of Bristol-Myers Squibb (BMS), the company said.
A federal court has blocked plans by Mylan Laboratories to launch amlodipine besylate, a generic version of Pfizer’s blockbuster drug Norvasc, during the drug’s pediatric exclusivity period.
Ritalin manufacturer Celgene, and its distributor, Novartis, could experience major losses in revenue if they lose patent litigation in federal court to block a generic version of their attention-deficit/hyperactivity disorder (ADHD) treatment, according to Celgene.
Separate earnings reports released by Barr and Watson show expenses and other charges related to acquisition activity were key factors that drove earnings downward for both companies in 2006.
One of the federal investigations into a reverse-payment deal involving generic Plavix found no violations of federal securities laws on the part of Bristol-Myers Squibb (BMS), the company said.